Darunavir-d9 (Synonyms: TMC114-d9) |
| Catalog No.GC47173 |
An internal standard for the quantification of darunavir
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1133378-37-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Darunavir-d9 is intended for use as an internal standard for the quantification of darunavir by GC- or LC-MS. Darunavir is an HIV-1 protease inhibitor.1 It is active against HIV-1LAI in MT-2 cells (IC50 = 3 nM) with a cytotoxic concentration (CC50) of 74.4 μM. Darunavir is also active against wild-type and multidrug-resistant clinical isolates of HIV-1 in phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMCs; IC50s = 3 and 3-29 nM, respectively). It inhibits cell-free diffusion and cell-to-cell spread of HIV-1 in Jurkat cell populations (IC50s = 2.5 and 2.8 nM, respectively).2 Formulations containing darunavir have been used in combination therapy for the treatment of HIV.
1.Koh, Y., Nakata, H., Maeda, K., et al.Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroAntimicrob. Agents Chemother.47(10)3123-3129(2003) 2.Titanji, B.K., Aasa-Chapman, M., Pillay, D., et al.Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cellsRetrovirology10161(2013)
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *